Andrew Guggenhime - Dec 14, 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Dec 14, 2023
Transactions value $
-$768,180
Form type
4
Date filed
12/18/2023, 04:01 PM
Previous filing
Nov 22, 2023
Next filing
Dec 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $74.9K +14K +17.62% $5.35 93.5K Dec 14, 2023 Direct
transaction PCVX Common Stock Sale -$843K -14K -14.98% $60.22 79.5K Dec 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -14K -3.37% $0.00 401K Dec 14, 2023 Common Stock 14K $5.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.
F2 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.